Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/165519
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Monteil, Vanessa | - |
dc.contributor.author | Kwon, Hyesoo | - |
dc.contributor.author | Prado, Patricia | - |
dc.contributor.author | Hagelkrüys, Astrid | - |
dc.contributor.author | Wimmer, Reiner A. | - |
dc.contributor.author | Stahl, Martin | - |
dc.contributor.author | Leopoldi, Alexandra | - |
dc.contributor.author | Garreta, Elena | - |
dc.contributor.author | Hurtado del Pozo, Carmen | - |
dc.contributor.author | Prosper, Felipe | - |
dc.contributor.author | Romero, Juan Pablo | - |
dc.contributor.author | Wirnberger, Gerald | - |
dc.contributor.author | Zhang, Haibo | - |
dc.contributor.author | Slutsky, Artur S. | - |
dc.contributor.author | Conder, Ryan | - |
dc.contributor.author | Montserrat, Núria | - |
dc.contributor.author | Mirazimi, Ali | - |
dc.contributor.author | Penninger, Josef M. | - |
dc.date.accessioned | 2020-06-15T07:44:01Z | - |
dc.date.available | 2021-04-24T05:10:19Z | - |
dc.date.issued | 2020-04-24 | - |
dc.identifier.uri | http://hdl.handle.net/2445/165519 | - |
dc.description.abstract | We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections. | ca |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | Elsevier | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1016/j.cell.2020.04.004 | - |
dc.relation.ispartof | Cell, 2020, vol. 181, num. 4, p. 905-913 | - |
dc.relation.uri | https://doi.org/10.1016/j.cell.2020.04.004 | - |
dc.rights | cc-by-nc-nd (c) Elsevier, 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) | - |
dc.subject.classification | Coronavirus | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.classification | Terapèutica | - |
dc.subject.other | Coronaviruses | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | Therapeutics | - |
dc.title | Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 | ca |
dc.type | info:eu-repo/semantics/article | ca |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/640525i/EU//REGMAMKID | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Publicacions de projectes de recerca finançats per la UE Articles publicats en revistes (Institut de Bioenginyeria de Catalunya (IBEC)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
L20_2020_Cell_181_905_OA.pdf | 4.21 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License